1112 ET - BioNTech expects its Covid-19 booster sales to stay relatively stable even if the government narrows its recommendations of who needs the shot. The Centers for Disease Control is scheduled to vote in June on a new recommendation for who should get the Covid-19 booster, which could narrow it to high-risk groups only. BioNTech, which rose to prominence for its partnership with Pfizer during the Covid-19 pandemic, says during an analyst call that many of the people still getting the booster are in high-risk groups already. The majority of Covid vaccines in the U.S. are going to people who are older than 65 or immunocompromised, which accounts for about 20% of Americans, management says. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
May 05, 2025 11:13 ET (15:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。